Market news

LH expands specialty testing and consumer services through acquisitions, partnerships and AI, while reimbursement and cost risks remain.

Labcorp dives on CMS 2027 Medicare lab-payment cuts; see why the selloff may be overdone, and the downside capped and why it’s a strong buy of LH stock—read now.

Labcorp Holdings (NYSE:LH) used its 2026 Investor Day to outline a push into targeted acquisitions and new lab technologies. Management emphasized capital deployment toward advanced lab management systems and expanded digital experiences for patients and providers. The company highlighted plans to integrate acquired platforms with its existing diagnostic infrastructure to streamline operations and data handling. Labcorp's renewed focus on acquisitions and digital lab tools only tells part of...

Labcorp (LH) reaffirmed its compound annual adjusted EPS growth guidance of 8.5% to 11.5% and compou

Labcorp says CMS Medicare lab payment cuts starting in 2027 won’t change its 2026–2029 growth outlook. Read more here.

The government thinks it's been overpaying Labcorp. They plan to stop doing that next year.

Quest Diagnostics (DGX) and Labcorp (LH) shares fell in Tuesday premarket trading after the Centers

Labcorp Holdings (LH) has an average rating of overweight and mean price target of $348.27, accordin

CMS will cut Medicare lab payments 15% in 2027, impacting Labcorp and Quest. Read more here.

Labcorp Holdings on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day. The health care company emphasized its innovation roadmap, technological advancements and solid financial expectations for the coming years. Reaffirming Financial Targets The...

2026-09-12. The following slide deck was published by Labcorp Holdings Inc.

Labcorp Holdings (LH) has an average rating of overweight and mean price target of $344.73, accordin

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today will host its 2026 Investor Day at 9 a.m. ET, where the company will provide an in-depth review of its growth strategy, innovation roadmap and long-term financial outlook. The event will highlight Labcorp's unique position at the intersection of diagnostics, biopharma, science and technology and how the company is creating long-term value for customers and shareholders.

Buying MLM gives Labcorp a wholly owned laboratory network that spans North America, Europe, Asia and Africa.

Labcorp Holdings (LH) said Tuesday it has acquired MLM Medical Labs, a global central and specialty

Labcorp Holdings (LH) has an average rating of overweight and mean price target of $344.73, accordin

Enterprise CISOs and cybersecurity leaders will share real-world lessons for strengthening Workforce Security, advancing Security Behavior Management, and reducing risk across humans and AI agentsAUSTIN, TX / ACCESS Newswire / August 31, 2026 / , the global leader in Human Risk Management (HRM), today announced the full speaker roster for HRMCon 2026, its annual Human Risk Management conference taking place September 10 in Austin, Texas, with a live virtual broadcast available worldwide.The line

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory solutions, today announced enhancements to the digital experience of Labcorp Global Trial Connect™, the company's portfolio of clinical trial services, data and technology that enhances and accelerates delivery. The newly redesigned platform introduces new capabilities across the Labcorp Sponsor™ and Labcorp Investigator™ portal experiences of Global Trial Connect, providing greater visibility across studies, simplify

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept. 15, at 11:30 a.m. ET.

Labcorp Holdings (NYSE: LH) introduced the Elecsys pTau-217 blood test, the first FDA-cleared single biomarker test for Alzheimer’s disease, expanding access through primary and specialty care. The Elecsys pTau-217 test is positioned to support clinical assessment of cognitive decline with a minimally invasive blood draw instead of more invasive procedures. Labcorp announced a long-term alliance with the National Association of Community Health Centers to support clinical leadership and...

Do Wall Street analysts favor Labcorp’s stock, given its solid performance?

BURLINGTON, N.C. , Aug. 24, 2026 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Dru...